Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.21.2
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Research and development:    
Compensation and benefits, net of related party reimbursements $ 7,174 $ 5,883
Clinical trial costs 4,718 3,955
Licensing costs 1,000 0
Consultants and outside services 791 3,209
Material manufacturing costs 765 882
Facilities and other 539 521
Total research and development 14,987 14,450
General and administrative:    
Compensation and benefits 4,887 3,782
Professional fees 2,124 1,169
Facilities and other 896 1,120
Total general and administrative 7,907 6,071
Total operating expenses 22,894 20,521
Operating loss (22,894) (20,521)
Non-operating income (expense):    
Change in fair value of derivative liabilities 1,789 0
Employee retention credit 515 0
Interest and other income 63 188
Interest expense (375) 0
Total non-operating income (expense), net 1,992 188
Net loss $ (20,902) $ (20,333)
Net loss per common share - basic and diluted (in dollars per share) $ (2.72) $ (3.54)
Weighted average number of common shares outstanding - basic and diluted (in shares) 7,671 5,751